To establish proof-of-concept that the drug tocilizumab, a monoclonal antibody that blocks interleukin-6 receptor is effective in decreasing clinical signs, symptoms, and laboratory evidence of COVID-19 pneumonitis. Begins April4, 2020; ends July, 2020. Here, IL6R is linked to COVID-19.